BlackRock Fund Advisors recently announced the acquisition of new stake in Organogenesis Holdings Inc. (NASDAQ:ORGO). The institutional investor has increased its shareholding in the Healthcare company by 15.55% to 10.41 million shares with purchase of 1.4 million shares. This fresh investment now brings its stake to 7.95% valued currently at $25.51 million. In addition, Soleus Capital Management LP raised its holdings by 0.87 million to 7.36 million shares. And The Vanguard Group, Inc. has lifted its position by 7.58% or 0.33 million shares – to 4.63 million shares.
With over 1.99 million Organogenesis Holdings Inc. (ORGO) shares trading Tuesday and a closing price of $2.16 on the day, the dollar volume was approximately $4.29 million. The shares have shown a negative half year performance of -42.40% and its price on 03/14/23 lost nearly -1.37%. Currently, there are 130.93M common shares owned by the public and among those 64.70M shares have been available to trade.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for ORGO have a consensus price objective of $11.00. The analysts have set the share’s price value over the next 12 months at a high of $11.00 and a low of $11.00. But an upside of 80.36% will see the stock hit the forecast high price target while median target price for the stock is $11.00.
Insiders at the company have transacted a total of 69 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 28 of these insider trades were purchases, accounting for 1,827,681 shares. Insider sales of the common stock occurred on 41 occasions, with total insider shares sold totaling 1,545,794 shares.
The top 3 mutual fund holders in Organogenesis Holdings Inc. are iShares Core S&P Small Cap ETF, Vanguard Total Stock Market Index, and Federated Hermes MDT Small Cap Co. iShares Core S&P Small Cap ETF owns 5.4 million shares of the company’s stock, all valued at over $13.23 million. The company bought an additional 13104.0 shares recently to bring their total holdings to about 4.12% of the shares outstanding. Federated Hermes MDT Small Cap Co bought 0.14 million shares to bring its total holdings to over 1.7 million shares at a value of $4.18 million. Federated Hermes MDT Small Cap Co now owns shares totaling to 1.30% of the shares outstanding.
Shares of Organogenesis Holdings Inc. (NASDAQ: ORGO) opened at $2.27, up $0.08 from a prior closing price of $2.19. However, the script later moved the day high at 2.2700, down -1.37%. The company’s stock has a 5-day price change of -6.49% and -18.49% over the past three months. ORGO shares are trading -19.70% year to date (YTD), with the 12-month market performance down to -71.65% lower. It has a 12-month low price of $2.12 and touched a high of $8.27 over the same period. ORGO has an average intraday trading volume of 894.05K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -13.93%, -17.04%, and -40.73% respectively.
Institutional ownership of Organogenesis Holdings Inc. (NASDAQ: ORGO) shares accounts for 43.20% of the company’s 130.93M shares outstanding. Mutual fund holders own 22.59%, while other institutional holders and individual stakeholders account for 60.81% and 20.58% respectively.
It has a market capitalization of $287.04M and a beta (3y monthly) value of 1.38. The stock’s trailing 12-month PE ratio is 18.46, while the earnings-per-share (ttm) stands at $0.12. The company has a PEG of 7.66 and a Quick Ratio of 2.60 with the debt-to-equity ratio at 0.27. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.60% over the week and 8.36% over the month.
Analysts forecast that Organogenesis Holdings Inc. (ORGO) will achieve an EPS of $0.05 for the current quarter, $0 for the next quarter and $0.25 for 2023. The lowest estimate earnings-per-share for the quarter is $0.05 while analysts give the company a high EPS estimate of $0.05. Comparatively, EPS for the current quarter was $0.39 a year ago. Earnings per share for the fiscal year are expected to decrease by -83.50%, and 266.67% over the next financial year. EPS should shrink at an annualized rate of 2.41% over the next five years, compared to 17.60% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Organogenesis Holdings Inc. (ORGO) as a “Hold” at a consensus score of 3.00. Specifically, 0 Wall Street analysts polled rate the stock as a buy, while 1 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
SVB Leerink was of a view on January 10, 2020 that the stock is Outperform, while Credit Suisse gave the stock Outperform rating on August 26, 2019, issuing a price target of $9- $10. Credit Suisse on their part issued Outperform rating on May 02, 2019.
Leave a Reply